{"id":"docetaxel-doc","safety":{"commonSideEffects":[{"rate":"75–80","effect":"Neutropenia"},{"rate":"50–60","effect":"Anemia"},{"rate":"25–35","effect":"Thrombocytopenia"},{"rate":"20–30","effect":"Peripheral neuropathy"},{"rate":"50–75","effect":"Alopecia"},{"rate":"30–40","effect":"Nausea and vomiting"},{"rate":"30–40","effect":"Diarrhea"},{"rate":"15–25","effect":"Mucositis"},{"rate":"5–10","effect":"Hypersensitivity reactions"}]},"_chembl":{"chemblId":"CHEMBL92","moleculeType":"Small molecule","molecularWeight":"807.89"},"_dailymed":{"setId":"8fb7d980-d6c7-468b-a9f0-adff16101a4b","title":"BEIZRAY ( DOCETAXEL ) KIT BEIZRAY ( DOCETAXEL ) KIT BEIZRAY (DOCETAXEL) INJECTION, SOLUTION [ZYDUS PHARMACEUTICALS USA INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Docetaxel is a taxane that binds to the β-tubulin subunit of microtubules and prevents their disassembly, leading to stabilization of the microtubule structure. This disrupts normal cell division by blocking cells in the G2/M phase of the cell cycle, ultimately triggering apoptosis in rapidly dividing cancer cells. It is effective against a broad range of solid tumors.","oneSentence":"Docetaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:39.549Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"},{"name":"Non-small cell lung cancer"},{"name":"Prostate cancer"},{"name":"Gastric cancer"},{"name":"Head and neck cancer"}]},"trialDetails":[{"nctId":"NCT05704829","phase":"PHASE2","title":"NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"West German Study Group","startDate":"2024-02-05","conditions":"HER2-positive Early Breast Cancer","enrollment":402},{"nctId":"NCT05712694","phase":"PHASE3","title":"Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)","status":"RECRUITING","sponsor":"Polaris Group","startDate":"2023-11-29","conditions":"Soft Tissue Sarcoma","enrollment":300},{"nctId":"NCT07031258","phase":"","title":"Evaluation of the Efficacy of Darolutamide Triplet Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-06","conditions":"Metastatic Hormone-sensitive Prostate Cancer, Darolutamide (DARO) in Combination With Androgen-deprivation Therapy (ADT) and Docetaxel (DOC)","enrollment":50},{"nctId":"NCT03317158","phase":"PHASE1, PHASE2","title":"Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder","status":"RECRUITING","sponsor":"Noah Hahn, M.D.","startDate":"2017-11-21","conditions":"Urothelial Carcinoma, Bladder Cancer","enrollment":55},{"nctId":"NCT06469060","phase":"PHASE2","title":"Neoadjuvant Immunochemotherapy for Adenocarcinoma of the Esophagogastric Junction","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2024-06-19","conditions":"Esophageal Cancer","enrollment":34},{"nctId":"NCT02931890","phase":"PHASE2","title":"Multicentric Randomised Trial for Resectable Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2017-12-21","conditions":"Gastric Cancer","enrollment":207},{"nctId":"NCT03887130","phase":"PHASE2","title":"Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","startDate":"2007-03-27","conditions":"Breast Cancer","enrollment":152},{"nctId":"NCT04172259","phase":"PHASE2","title":"ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2019-01-10","conditions":"Breast Cancer, Neoadjuvant Chemotherapy","enrollment":156},{"nctId":"NCT02393248","phase":"PHASE1, PHASE2","title":"Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2015-02-27","conditions":"Lung Cancer, Solid Tumor, Gastric Cancer","enrollment":201},{"nctId":"NCT02419742","phase":"PHASE4","title":"Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-08-18","conditions":"Breast Cancer","enrollment":110},{"nctId":"NCT01207011","phase":"PHASE3","title":"Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Sumitomo Pharma Co., Ltd.","startDate":"2010-10","conditions":"Lung Cancer","enrollment":202},{"nctId":"NCT01362374","phase":"PHASE1","title":"Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2011-07-11","conditions":"Neoplasms","enrollment":122},{"nctId":"NCT02512315","phase":"PHASE3","title":"A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-08","conditions":"Nasopharyngeal Carcinoma","enrollment":192},{"nctId":"NCT00285415","phase":"PHASE2","title":"A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed Pelvic Irradiation","status":"TERMINATED","sponsor":"Carilion Clinic","startDate":"2005-04","conditions":"Advanced Endometrial Adenocarcinoma, Stage III A, B, C","enrollment":46},{"nctId":"NCT02115204","phase":"PHASE3","title":"4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF","status":"COMPLETED","sponsor":"West German Study Group","startDate":"2000-06","conditions":"Breast Cancer","enrollment":2011},{"nctId":"NCT01283204","phase":"PHASE2","title":"Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2010-03-09","conditions":"Recurrent or Metastatic Gastric Cancer","enrollment":180},{"nctId":"NCT00934856","phase":"PHASE1, PHASE2","title":"A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-07","conditions":"Breast Cancer","enrollment":98},{"nctId":"NCT03015727","phase":"PHASE3","title":"Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2016-12","conditions":"Locally Advanced Nasopharyngeal Carcinoma","enrollment":440},{"nctId":"NCT00503984","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients","status":"TERMINATED","sponsor":"University of Miami","startDate":"2007-05","conditions":"Prostate Cancer, Pain","enrollment":22},{"nctId":"NCT01891123","phase":"NA","title":"Explore the Individual Treatment of Docetaxel and Paclitaxel in NSCLC, NPC and BRC by PK-guided Dosing Strategy","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2013-06","conditions":"Non-small Cell Lung Cancer, Breast Cancer, Nasal Cancer","enrollment":300},{"nctId":"NCT02179567","phase":"PHASE2","title":"Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC","status":"TERMINATED","sponsor":"Hellenic Oncology Research Group","startDate":"2010-03","conditions":"NSCLC","enrollment":26},{"nctId":"NCT01254279","phase":"PHASE3","title":"Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-12","conditions":"Prostate Cancer Metastatic","enrollment":984},{"nctId":"NCT02181101","phase":"PHASE3","title":"Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2005-09","conditions":"Breast Neoplasms","enrollment":3754},{"nctId":"NCT00288002","phase":"PHASE3","title":"Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2005-01","conditions":"Breast Cancer","enrollment":1500},{"nctId":"NCT00047099","phase":"PHASE3","title":"Combination Chemotherapy in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2001-08","conditions":"Breast Cancer","enrollment":446},{"nctId":"NCT00670878","phase":"PHASE3","title":"Studying the Benefits of Adjuvant Sequential vs. Combined Taxane Based Chemotherapy, Followed by Different Biological Treatment Strategies in Early, HER2-positive Breast Cancer","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2008-06","conditions":"Breast Cancer","enrollment":799},{"nctId":"NCT00793377","phase":"PHASE3","title":"Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"","conditions":"Primary Breast Cancer","enrollment":913}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"FEBRILE NEUTROPENIA"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Docetaxel Injection"],"phase":"marketed","status":"active","brandName":"Docetaxel (DOC)","genericName":"Docetaxel (DOC)","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Docetaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells. Used for Metastatic breast cancer, Non-small cell lung cancer, Prostate cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}